Menu
Search
|

Menu

Close
X

Ucb SA UCB.BR (Brussels Stock Exchange)

70.24 EUR
-- (--)
As of Jul 19
chart
Previous Close 70.24
Open --
Volume --
3m Avg Volume 324,466
Today’s High --
Today’s Low --
52 Week High 71.76
52 Week Low 56.55
Shares Outstanding (mil) 194.51
Market Capitalization (mil) 11,689.79
Forward P/E 17.05
Dividend (Yield %) 1.15 ( 1.34 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.84 Mean rating from 19 analysts

KEY STATS

Revenue (mm, EUR)
FY17
4,530
FY16
4,147
FY15
3,876
EPS (EUR)
FY17
3.994
FY16
2.883
FY15
1.374
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
17.05
32.76
Price to Sales (TTM)
vs sector
2.66
5.73
Price to Book (MRQ)
vs sector
2.01
5.47
Price to Cash Flow (TTM)
vs sector
12.68
23.29
Total Debt to Equity (MRQ)
vs sector
28.10
16.84
LT Debt to Equity (MRQ)
vs sector
27.61
12.51
Return on Investment (TTM)
vs sector
8.89
14.61
Return on Equity (TTM)
vs sector
12.31
16.34

EXECUTIVE LEADERSHIP

Jean-Christophe Tellier
Chairman of the Executive Committee, Chief Executive Officer, Executive Director, Since 2015
Salary: €70,000.00
Bonus: --
Evelyn Diego du Monceau de Bergendal
Non-Executive Chair of the Board, Since 2017
Salary: €175,000.00
Bonus: --
Pierre Gurdjian
Independent Non-Executive Vice Chairman of the Board, Since 2017
Salary: €93,333.00
Bonus: --
Detlef Thielgen
Executive Vice President, Chief Financial Officer, Member of the Executive Committee, Since 2007
Salary: --
Bonus: --
Charl van Zyl
Executive Vice President, Chief Operating Officer, Member of the Executive Committee, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Allee de la Recherche, 60
ANDERLECHT     1070

Phone: +322.5599999

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

SPONSORED STORIES